Compare Adaptive Biotechnologies Corp (ADPT) vs M&T Bank Corporation (MTB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs M&T Bank Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $20.09 (market cap $3.33B), while M&T Bank Corporation trades at $233.89 (market cap $35.11B). The key difference: M&T Bank Corporation is far larger — about 10.5× Adaptive Biotechnologies Corp's market cap, and M&T Bank Corporation pays a 2.5% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | MTB | |
|---|---|---|
Market Cap | $3.33B | $35.11B |
Sector | Health | Financials |
52-Week High | $22.37 | $241.95 |
52-Week Low | $10.24 | $178.63 |
Enterprise Value | $3.19B | — |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MTB trades at $239.75, up 0.36% today, near the consensus price target of $241.56. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $9.63B in 2025, with a strong net income margin of 29.59%. Recent news highlights upcoming Q2 2026 earnings and strategic leadership appointments, reinforcing operational focus.
The outlook is cautiously positive, supported by solid fundamentals and analyst consensus, but risks include elevated investing cash outflows and sensitivity to interest rate changes. The stock presents a value opportunity with a reasonable P/E of 13.47, though investor sentiment remains mixed ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
